English  |  中文
Please enter exact key words

Equity Investment


Protheragen is committed to invest in the early stage first-in-class drug development projects, using our funds based in China. Different from other investment companies, our strategy appreciates the uniqueness of an innovation, helping scientists with bright program ideas and persuasive preclinical results to build their startup business from scratch. We support seed capital to accelerate the project, and can continue bringing in following rounds for late-stage development depending on the project.

Investment plan:

● Invest and incubate 100 early stage novel drug R&D projects.
● Each selected project receives US $100-300 million.

Areas of investment:

Protein/Polypeptide Therapeutics Immunotherapies CAR-T Therapies Stem Cells Oncolytic Viruses Gene Therapies Vaccines Small Molecules

Investment criteria:

Project needs to be innovative and with international IP protection.

No restriction on the disease types.

Consider companies with outsourced early R&D to avoid investment in fixed assets

Investment fund is for R&D use only

Protheragen Inc.

2200 Smithtown Avenue, Room 1, Ronkonkoma,
NY 11779-7329, USA
Phone: 1-516-765-9461    Fax: 1-516-927-0118
Email: info@protheragen.com

Opening Hours

Monday — Sunday: 9am — 6pm